Osilodrostat

Drug Profile

Osilodrostat

Alternative Names: LCI-699

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Novartis
  • Class Antihypertensives; Fluorobenzenes; Imidazoles; Nitriles; Pyridines; Small molecules
  • Mechanism of Action Aldosterone synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Pituitary ACTH hypersecretion
  • Phase II Cushing syndrome
  • Discontinued Heart failure; Hypertension; Solid tumours

Most Recent Events

  • 29 Apr 2016 Phase-III clinical trials in Pituitary ACTH hypersecretion in Greece, Belgium (PO) (EudraCT2014-004092-23)
  • 29 Apr 2016 Novartis initiates the phase III LINC-4 trial in Pituitary ACTH hypersecretion in Spain (EudraCT2014-004092-23)
  • 27 Feb 2016 Novartis plans the phase III LINC-4 trial for Pituitary ACTH hypersecretion in Greece, Thailand, Poland, Turkey, Russia, Brazil, Belgium, Spain, Denmark, Switzerland and USA (PO) (NCT02697734)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top